Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mohs Surgery | 10 | 2024 | 37 | 2.960 |
Why?
|
| Skin Neoplasms | 12 | 2024 | 880 | 2.620 |
Why?
|
| Dermatologic Surgical Procedures | 3 | 2024 | 37 | 1.420 |
Why?
|
| Nose Neoplasms | 2 | 2022 | 30 | 1.150 |
Why?
|
| Nose | 3 | 2023 | 102 | 1.090 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2019 | 15 | 1.020 |
Why?
|
| Rhinoplasty | 2 | 2023 | 48 | 0.900 |
Why?
|
| Nail Diseases | 2 | 2015 | 15 | 0.860 |
Why?
|
| Surgical Flaps | 3 | 2024 | 185 | 0.850 |
Why?
|
| Skin Transplantation | 2 | 2013 | 57 | 0.800 |
Why?
|
| Skin | 2 | 2018 | 516 | 0.730 |
Why?
|
| Counseling | 1 | 2023 | 233 | 0.720 |
Why?
|
| Lidocaine | 2 | 2024 | 42 | 0.700 |
Why?
|
| Anesthetics, Local | 2 | 2024 | 81 | 0.660 |
Why?
|
| Cicatrix | 2 | 2012 | 122 | 0.650 |
Why?
|
| Acrospiroma | 1 | 2019 | 4 | 0.610 |
Why?
|
| Facial Neoplasms | 1 | 2019 | 21 | 0.600 |
Why?
|
| Bandages | 2 | 2024 | 54 | 0.590 |
Why?
|
| Fissure in Ano | 1 | 2018 | 6 | 0.570 |
Why?
|
| Vulvar Diseases | 1 | 2018 | 11 | 0.570 |
Why?
|
| Infliximab | 1 | 2018 | 65 | 0.560 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2014 | 744 | 0.540 |
Why?
|
| Alternariosis | 1 | 2016 | 1 | 0.520 |
Why?
|
| Leg Dermatoses | 1 | 2016 | 2 | 0.520 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 119 | 0.510 |
Why?
|
| Immunocompetence | 1 | 2016 | 30 | 0.510 |
Why?
|
| Methotrexate | 1 | 2018 | 313 | 0.490 |
Why?
|
| Drug Storage | 1 | 2016 | 18 | 0.490 |
Why?
|
| Drug Contamination | 1 | 2016 | 34 | 0.490 |
Why?
|
| Syringes | 1 | 2016 | 22 | 0.480 |
Why?
|
| Security Measures | 1 | 2015 | 5 | 0.480 |
Why?
|
| Skin Diseases, Genetic | 1 | 2015 | 20 | 0.470 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 263 | 0.470 |
Why?
|
| Contracture | 1 | 2015 | 27 | 0.470 |
Why?
|
| Dermatology | 1 | 2015 | 29 | 0.470 |
Why?
|
| Epinephrine | 1 | 2016 | 146 | 0.450 |
Why?
|
| Photography | 1 | 2015 | 73 | 0.450 |
Why?
|
| Crohn Disease | 1 | 2018 | 290 | 0.450 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2015 | 121 | 0.450 |
Why?
|
| Skin Diseases | 1 | 2015 | 136 | 0.420 |
Why?
|
| Models, Anatomic | 1 | 2015 | 103 | 0.420 |
Why?
|
| Cyanoacrylates | 1 | 2013 | 11 | 0.420 |
Why?
|
| Peripheral Nerves | 1 | 2014 | 81 | 0.420 |
Why?
|
| Tissue Adhesives | 1 | 2013 | 36 | 0.410 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2014 | 39 | 0.410 |
Why?
|
| Eyelid Neoplasms | 1 | 2014 | 28 | 0.410 |
Why?
|
| Nails | 1 | 2013 | 21 | 0.410 |
Why?
|
| Ear Neoplasms | 1 | 2013 | 14 | 0.390 |
Why?
|
| Sunscreening Agents | 1 | 2012 | 4 | 0.380 |
Why?
|
| Ointments | 1 | 2012 | 9 | 0.380 |
Why?
|
| Zinc Oxide | 1 | 2012 | 13 | 0.380 |
Why?
|
| Bowen's Disease | 1 | 2011 | 4 | 0.360 |
Why?
|
| Clinical Competence | 1 | 2018 | 1018 | 0.340 |
Why?
|
| Carcinoma in Situ | 1 | 2011 | 72 | 0.340 |
Why?
|
| Explosive Agents | 1 | 2010 | 1 | 0.340 |
Why?
|
| Ochronosis | 1 | 2010 | 4 | 0.340 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 3907 | 0.340 |
Why?
|
| Postoperative Care | 1 | 2013 | 306 | 0.330 |
Why?
|
| Humans | 28 | 2024 | 126753 | 0.320 |
Why?
|
| Metals | 1 | 2010 | 56 | 0.320 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 589 | 0.280 |
Why?
|
| Postoperative Hemorrhage | 1 | 2008 | 81 | 0.270 |
Why?
|
| Fibrinolytic Agents | 1 | 2008 | 198 | 0.250 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2507 | 0.240 |
Why?
|
| Aged | 9 | 2024 | 20344 | 0.240 |
Why?
|
| Wound Healing | 2 | 2023 | 447 | 0.230 |
Why?
|
| Biopsy | 2 | 2019 | 1236 | 0.230 |
Why?
|
| Population Health | 1 | 2024 | 36 | 0.200 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2024 | 50 | 0.200 |
Why?
|
| Nasolabial Fold | 1 | 2022 | 1 | 0.200 |
Why?
|
| Retrospective Studies | 6 | 2023 | 17005 | 0.190 |
Why?
|
| Melanoma | 2 | 2024 | 898 | 0.180 |
Why?
|
| Suture Techniques | 1 | 2023 | 169 | 0.180 |
Why?
|
| Male | 11 | 2024 | 62543 | 0.170 |
Why?
|
| Patient Satisfaction | 1 | 2024 | 456 | 0.170 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 6668 | 0.170 |
Why?
|
| Treatment Outcome | 5 | 2024 | 12546 | 0.170 |
Why?
|
| Chin | 1 | 2019 | 4 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1861 | 0.150 |
Why?
|
| Female | 11 | 2024 | 68330 | 0.150 |
Why?
|
| Roman World | 1 | 2018 | 2 | 0.140 |
Why?
|
| Greece, Ancient | 1 | 2018 | 9 | 0.140 |
Why?
|
| History, Medieval | 1 | 2018 | 27 | 0.140 |
Why?
|
| History, Ancient | 1 | 2018 | 52 | 0.140 |
Why?
|
| History, 19th Century | 1 | 2018 | 110 | 0.140 |
Why?
|
| Granuloma | 1 | 2018 | 62 | 0.140 |
Why?
|
| India | 1 | 2018 | 228 | 0.140 |
Why?
|
| Europe | 1 | 2018 | 359 | 0.130 |
Why?
|
| Physical Examination | 1 | 2018 | 160 | 0.130 |
Why?
|
| Econazole | 1 | 2016 | 2 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2018 | 226 | 0.130 |
Why?
|
| Itraconazole | 1 | 2016 | 23 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2018 | 369 | 0.130 |
Why?
|
| Antirheumatic Agents | 1 | 2018 | 118 | 0.120 |
Why?
|
| Buffers | 1 | 2016 | 28 | 0.120 |
Why?
|
| Colony Count, Microbial | 1 | 2016 | 81 | 0.120 |
Why?
|
| Bicarbonates | 1 | 2016 | 98 | 0.120 |
Why?
|
| Skin Aging | 1 | 2015 | 12 | 0.120 |
Why?
|
| Vitamin A | 1 | 2015 | 57 | 0.120 |
Why?
|
| Hip Joint | 1 | 2015 | 50 | 0.120 |
Why?
|
| Range of Motion, Articular | 1 | 2015 | 80 | 0.120 |
Why?
|
| Vasoconstrictor Agents | 1 | 2016 | 131 | 0.110 |
Why?
|
| Drug Combinations | 1 | 2016 | 270 | 0.110 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 196 | 0.110 |
Why?
|
| Steroids | 1 | 2015 | 157 | 0.110 |
Why?
|
| Eccrine Glands | 1 | 2014 | 1 | 0.110 |
Why?
|
| Frozen Sections | 1 | 2014 | 26 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2016 | 290 | 0.110 |
Why?
|
| Hair Follicle | 1 | 2014 | 33 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2015 | 824 | 0.100 |
Why?
|
| Pressure | 1 | 2013 | 123 | 0.100 |
Why?
|
| Life Expectancy | 1 | 2012 | 53 | 0.100 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2014 | 226 | 0.090 |
Why?
|
| Fibrosis | 1 | 2014 | 400 | 0.090 |
Why?
|
| Administration, Topical | 1 | 2012 | 110 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 634 | 0.090 |
Why?
|
| Adult | 4 | 2024 | 30410 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2883 | 0.090 |
Why?
|
| Postoperative Period | 1 | 2012 | 323 | 0.090 |
Why?
|
| Middle Aged | 5 | 2024 | 27697 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1597 | 0.080 |
Why?
|
| Cytoplasmic Granules | 1 | 2010 | 50 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 3662 | 0.080 |
Why?
|
| Adolescent | 2 | 2018 | 20002 | 0.070 |
Why?
|
| Aging | 1 | 2015 | 1193 | 0.070 |
Why?
|
| Inflammation | 1 | 2014 | 1420 | 0.060 |
Why?
|
| Time Factors | 1 | 2016 | 6134 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 1137 | 0.060 |
Why?
|
| Anesthesia, Local | 1 | 2024 | 35 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2024 | 348 | 0.050 |
Why?
|
| Sutures | 1 | 2023 | 62 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2024 | 1584 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2024 | 3314 | 0.030 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2015 | 17 | 0.030 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2015 | 16 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2015 | 75 | 0.030 |
Why?
|
| Child | 1 | 2015 | 25101 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 396 | 0.030 |
Why?
|
| Risk Factors | 1 | 2008 | 10555 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 6214 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2015 | 420 | 0.030 |
Why?
|
| Comorbidity | 1 | 2012 | 1559 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 17596 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 33051 | 0.010 |
Why?
|